榴莲视频

Purpose

Despite guidelines recommending bone-modifying agents (BMAs) to decrease skeletal-related events (SREs) in men with metastatic castration-resistant prostate cancer (mCRPC), BMAs are underutilized. In this retrospective cohort study, we report the factors associated with BMA use in a national health care delivery system.

Methods

We used the Veterans Affairs Corporate Data Warehouse to identify men with mCRPC between 2010 and 2017. BMA prescribing frequency was evaluated, and the association between patient- and disease-specific factors with BMA use was assessed using multivariable logistic regression.

Results

Among 3,980 men identified with mCRPC (mean age 73.5 years, 29% Black), 47% received a BMA; median time to BMA from start of mCRPC treatment was 102 days. Factors associated with BMA use included previous BMA use (adjusted odds ratio [aOR] 7.81, 95% CI 6.48-9.47), diagnosis code for bone metastases (aOR, 1.26, 95% CI 1.08-1.46), and concomitant corticosteroid use (aOR 1.53, 95% CI 1.29-1.82). Decreased BMA use was associated with advancing age (aOR 0.85 per 10 years, 95% CI 0.78-0.92], Charlson comorbidity index ≥2 (aOR 0.76, 95% CI 0.63-0.93), Black race (aOR 0.83, 95% CI 0.70-0.98), and decreased estimated glomerular filtration rate (eGFR; aOR 0.19, 95% CI 0.11- 0.32) for eGFR 0-29 mL/minutes; aOR 0.76, 95% CI 0.64-0.91 for 30-59 mL/minutes).

Conclusion

Patients who are older, Black, or have more comorbidities are less likely to receive guideline concordant care to prevent SREs. These observations highlight the unique challenges of caring for patients with mCRPC and the need for future studies to increase BMA use in these populations.

Read an interview about the study here.